4.5 Article

Influence of blood pressure on the effects of low-dose asprin in elderly patients with multiple atherosclerotic risks

Journal

JOURNAL OF HYPERTENSION
Volume 37, Issue 6, Pages 1301-1307

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/HJH.0000000000002034

Keywords

antiplatelet agent; bleeding events; elderly individuals; hypertension; primary prevention

Funding

  1. Japanese Ministry of Health, Labor, and Welfare
  2. Wacksman Foundation of Japan
  3. AstraZeneca
  4. Daiichi Sankyo
  5. Dainippon Sumitomo Pharma
  6. Kowa
  7. Kyowa Hakko Kirin
  8. MSD
  9. Mitsubishi Tanabe Pharma
  10. Pfizer
  11. Takeda
  12. Bayer
  13. Boehringer Ingelheim
  14. Otsuka
  15. Astellas Pharma
  16. Aska
  17. Kissei Pharmaceutical
  18. Shionogi
  19. Astellas
  20. Sanofi-Aventis
  21. Chugai
  22. Bristol-Myers Squibb
  23. Nippon Shinyaku

Ask authors/readers for more resources

Objective: We examined whether the efficacy of low-dose acetylsalicylic acid (aspirin) for primary prevention of cardiovascular events is influenced by blood pressure (BP) using data from patients aged 60-85 years with hypertension, dyslipidemia, and/or diabetes, but without cardiovascular disease of the Japanese Primary Prevention Project. Methods: All patients had received aspirin (100 mg/day) or no aspirin. BP subgroups were defined as low (average SBP from the baseline to the year of the events <130 mmHg), moderate (>= 130 and <140 mmHg), and high (>= 140 mmHg). The mean duration of follow-up was 5.02 years. Results: In hypertensive patients (n = 12278) aspirin had no significant impact on the primary outcome of death from cardiovascular disease, nonfatal stroke, and nonfatal myocardial infarction. On the other hand, aspirin increased the incidence of serious extracranial hemorrhage [hazard ratio, 1.81; 95% confidence interval (CI), 1.18-2.77; P = 0.0064] and tended to increase hemorrhagic stroke (hazard ratio, 1.75; CI, 0.99-3.07; P = 0.053). Aspirin had no effect on the primary outcome in any of the BP subgroups, and was associated with increased hemorrhagic stroke in the high BP group (hazard ratio, 3.51; CI, 1.29-9.51; P = 0.014); serious extracranial hemorrhage was elevated or tended to elevate in the moderate (hazard ratio, 2.53; CI, 1.18-5.45; P = 0.017) and high (hazard ratio, 2.14; CI, 1.00-4.56; P = 0.050) BP groups. Conclusion: In aged Japanese hypertensive patients, these data demonstrated no overall benefit of low-dose aspirin therapy although treatment was associated with an elevated risk of hemorrhagic events.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available